Hikari Power Ltd cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 44.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 102,500 shares of the company’s stock after selling 80,900 shares during the period. Hikari Power Ltd’s holdings in Zoetis were worth $5,331,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock worth $319,000 after buying an additional 26 shares during the period. Nordea Investment Management AB boosted its position in shares of Zoetis by 0.7% in the second quarter. Nordea Investment Management AB now owns 24,432 shares of the company’s stock valued at $1,160,000 after buying an additional 163 shares during the last quarter. Henderson Group PLC boosted its position in shares of Zoetis by 1.7% in the second quarter. Henderson Group PLC now owns 73,089 shares of the company’s stock valued at $3,468,000 after buying an additional 1,200 shares during the last quarter. First Citizens Bank & Trust Co. bought a new position in shares of Zoetis during the second quarter valued at about $587,000. Finally, LMR Partners LLP bought a new position in shares of Zoetis during the second quarter valued at about $1,747,000. 93.49% of the stock is owned by hedge funds and other institutional investors.
Shares of Zoetis Inc. (NYSE:ZTS) traded up 0.87% during trading on Wednesday, hitting $54.25. The stock had a trading volume of 425,245 shares. Zoetis Inc. has a 1-year low of $38.26 and a 1-year high of $54.72. The firm has a market capitalization of $26.79 billion, a P/E ratio of 39.11 and a beta of 1.07. The stock’s 50-day moving average price is $52.97 and its 200 day moving average price is $51.16.
Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.46 by $0.06. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same period last year, the business posted $0.50 EPS. The company’s revenue was up 2.2% compared to the same quarter last year. On average, analysts anticipate that Zoetis Inc. will post $1.94 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.78%. This is an increase from Zoetis’s previous quarterly dividend of $0.10. The ex-dividend date is Wednesday, January 18th. Zoetis’s dividend payout ratio (DPR) is currently 30.44%.
Several research analysts recently issued reports on the company. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $56.00 target price on the stock in a research report on Thursday, December 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $62.00 target price on shares of Zoetis in a research report on Tuesday, December 20th. Stifel Nicolaus reaffirmed a “buy” rating and set a $58.00 target price on shares of Zoetis in a research report on Wednesday, October 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $61.00 target price on shares of Zoetis in a research report on Thursday, December 15th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $59.00 target price on shares of Zoetis in a research report on Friday, December 23rd. Three research analysts have rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $57.67.
In other Zoetis news, insider Roxanne Lagano sold 9,797 shares of the stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $50.43, for a total transaction of $494,062.71. Following the sale, the insider now directly owns 8,063 shares in the company, valued at approximately $406,617.09. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kristin C. Peck sold 10,092 shares of the stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $49.55, for a total value of $500,058.60. Following the sale, the insider now owns 22,768 shares in the company, valued at $1,128,154.40. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).